The National Institute on Aging (NIA) awarded a $320,143 Project Grant under the Aging Research (CFDA 93.866) program to Mayo Clinic to determine the diagnostic utility of blood plasma biomarkers and their relation to pathophysiology in patients with atypical Alzheimer's disease (AD). The project will leverage existing blood samples, clinical data, and neuroimaging from 210 patients to:
-
Assess the value of blood plasma measures as diagnostic biomarkers in atypical AD patients, evaluating if the biomarkers could differentiate atypical AD patients from healthy controls and patients with similar clinical syndromes but without AD.
-
Assess the value of blood plasma measures as disease biomarkers/outcome measures in atypical AD, examining their relation to clinical outcomes and aspects of brain pathophysiology, including amyloid/tau burden, brain metabolism, and brain volume.
This innovative research proposal aims to improve diagnosis and reduce delays for atypical AD patients, who often do not present with memory loss but deficits in non-memory domains. The results could support incorporating plasma biomarkers into clinical practice and aid patient selection/disease outcome measures for AD clinical trials. The award period is from January 1, 2025 to December 31, 2026.
Generated 3/4/25, 7:23 AM